What are the diagnostic criteria for chronic kidney disease (CKD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

CKD Diagnostic Criteria

Chronic kidney disease is diagnosed when abnormalities in kidney structure or function persist for at least 3 months, specifically defined as eGFR <60 mL/min/1.73 m² and/or urine albumin-to-creatinine ratio (ACR) ≥30 mg/g (≥3 mg/mmol) and/or other markers of kidney damage such as hematuria or structural abnormalities. 1, 2

Core Diagnostic Requirements

The diagnosis requires TWO measurements over at least 3 months to establish chronicity 2. A single abnormal value does not confirm CKD—it could represent acute kidney injury or acute kidney disease rather than chronic disease.

Primary Diagnostic Parameters

Test both parameters simultaneously:

  • eGFR <60 mL/min/1.73 m² (calculated using creatinine-based equations, preferably the 2021 CKD-EPI equation without race) 1, 2
  • Urine ACR ≥30 mg/g (≥3 mg/mmol) measured in a spot morning urine sample 2

Either parameter alone is sufficient for diagnosis if persistent for ≥3 months, but both should always be measured for complete assessment 1, 3.

Additional Markers of Kidney Damage

CKD can also be diagnosed with normal eGFR (≥60 mL/min/1.73 m²) if other persistent abnormalities exist:

  • Hematuria (after excluding urological causes)
  • Structural abnormalities on imaging (reduced kidney size, cortical thinning, cysts, hydronephrosis)
  • Pathological findings (fibrosis, atrophy on biopsy)
  • Tubular disorders 1, 2, 3

Establishing Chronicity

Proof of chronicity can be established through:

  1. Review of past eGFR measurements showing persistent reduction
  2. Review of past albuminuria/proteinuria measurements
  3. Imaging findings (reduced kidney size, cortical thinning)
  4. Kidney biopsy showing fibrosis/atrophy
  5. Medical history of conditions causing CKD (diabetes, hypertension)
  6. Repeat measurements within and beyond the 3-month timeframe 4

Critical caveat: Do not assume chronicity from a single abnormal result—this could represent acute kidney injury requiring different management 4.

Enhanced Accuracy Testing

When creatinine-based eGFR may be inaccurate, measure cystatin C-based eGFR 2. The combined creatinine-cystatin C equation (eGFRcr-cys) provides superior accuracy and reduces racial/ethnic bias 1, 4.

Use cystatin C when:

  • Abnormal muscle mass (very high or very low for age/sex)
  • Drugs interfering with creatinine secretion
  • More precise GFR assessment needed for clinical decisions
  • Confirming low eGFR before major treatment decisions 2

Staging System

CKD is staged using the CGA system (Cause, GFR category, Albuminuria category) 2:

GFR Categories (G):

  • G1: ≥90 mL/min/1.73 m²
  • G2: 60-89 mL/min/1.73 m²
  • G3a: 45-59 mL/min/1.73 m²
  • G3b: 30-44 mL/min/1.73 m²
  • G4: 15-29 mL/min/1.73 m²
  • G5: <15 mL/min/1.73 m² (kidney failure)

Albuminuria Categories (A):

  • A1: <30 mg/g (<3 mg/mmol) - normal to mildly increased
  • A2: 30-300 mg/g (3-30 mg/mmol) - moderately increased
  • A3: >300 mg/g (>30 mg/mmol) - severely increased

Common Pitfalls to Avoid

  1. Don't diagnose CKD from a single measurement—always confirm with repeat testing after 3 months 2

  2. Don't skip albuminuria testing—screening is severely underutilized, with less than half of diabetic patients screened annually in typical US practice 1

  3. Don't use race-based eGFR equations—the 2021 CKD-EPI equation without race is now standard 1

  4. Don't ignore temporary causes of abnormal results—dehydration, acute illness, medications, and urinary tract infections can cause spurious elevations in creatinine or albuminuria 1

  5. Don't delay treatment while waiting for chronicity confirmation—if CKD is highly likely based on clinical context, initiate evidence-based treatments immediately 4

Risk Stratification

The combination of GFR and albuminuria categories determines risk for CKD progression and cardiovascular events 2, 5:

  • Low risk: eGFR ≥60 with ACR <3 mg/mmol
  • Moderate risk: eGFR ≥60 with ACR 3-30, OR eGFR 45-59 with ACR <3
  • High risk: eGFR ≥60 with ACR >30, OR eGFR 45-59 with ACR 3-30, OR eGFR 30-44 with ACR <3
  • Very high risk: eGFR <30 at any albuminuria level, OR eGFR 30-59 with ACR >30

This risk stratification directly guides treatment intensity and monitoring frequency 2, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.